Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by Dandy07on Sep 11, 2018 4:46pm
238 Views
Post# 28600251

RE:RE:Bertilimumab Fast Tracked!

RE:RE:Bertilimumab Fast Tracked!Well believe it or not, It will be coming. it is based on Immune initiating its Phase II/III study.  I read it iCO's prospectus from a sedar document and I quote:

Development Status:

BP Study:


" iCo-008 is currently in Phase II testing for the treatment of BP. IMMUNE plans to seek an end to Phase II meeting with the FDA by the end of 2018 to discuss the planned Phase II/III study as well as important manufacturing plans. IMMUNE could be in a position to launch a pivotal Phase II/III study in 2019. Under the terms of the IMMUNE License Agreement, the initiation of a pivotal study would trigger a milestone payment to the Company."

Now obviously we know they have been fast tracked,and what they stated about starting that trial as early as 2019 seems to be on track.  So it's only a matter of time until iCO recieves some payments which should help with its phase II study if that's what they are waiting for rather than seeking to issue more shares as an offering or any other financial deal.  There's still the possibility of both I suppose - partnership/financing with that partner and/or Milestone payments.
If anyone wants to look at the prospectus https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00024061

If the link doesn't work then you can go to https://www.sedar.com/search/search_form_pc_en.htm  and then search iCO Therapeautics Inc.  The prospectus was filed Aug 19, 2018 and is titled,  Final short form prospectus - English.   Hopefully that clears things up because I know a lot of people didn't know when they were expected to receive it.  I've been following this forum for like a year and a half and I wanted to start contributing useful and exciting information. There was just too much garbage for a while..Times are getting exciting!! 
<< Previous
Bullboard Posts
Next >>